Artera Launches Registry Trial to Measure Real-World Impact and Outcomes of its Prostate Test
SAN FRANCISCO--(BUSINESS WIRE)-- Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced the launch of its DIRECT-AI registry study. This study will assess how the ArteraAI Prostate Test influences treatment decision-making between clinicians and patients with localized prostate cancer. Additionally, the study will monitor participants to evaluate their long-term cancer outcomes, reinforcing Artera's commitment to advancing personalized cancer treatment and identifying future opportunities for test optimization.
The DIRECT-AI study centers on the award-winning ArteraAI Prostate Test—the only test included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for localized prostate cancer that can both predict therapy benefit and prognosticate long-term outcomes.
"Harnessing the power of AI, the ArteraAI Prostate Test marks a significant advancement in the personalized treatment of localized prostate cancer. Through the DIRECT-AI registry, we are rigorously evaluating how this technology can enhance clinical decision-making and improve patient outcomes, providing clinicians and patients with the most accurate, tailored insights available," said Dr. Tim Showalter, Chief Medical Officer at Artera.
The study is structured into two phases. The initial phase captures real-world insights into how the Artera Prostate Test informs clinical decision-making, with feedback collected from participating clinicians and patients. The second phase will monitor long-term health outcomes at key intervals of 2 and 5 years, looking at endpoints such as distant metastasis, survival rates, and treatment effectiveness. This research will help Artera understand how its test impacts cancer outcomes and monitor its performance so that it can be improved for patients in the future.
Any patient receiving the commercial ArteraAI Prostate Test and whose ordering physician is associated with an enrolling clinic is eligible to participate in the study. Patients must have localized prostate cancer and must not have started or received treatment for their condition. The study is non-interventional, meaning it does not require additional procedures or tests, and there will be no changes to the care participants receive, regardless of their participation.
For clinics participating in the DIRECT-AI Registry, physicians can enroll all patients for whom they order an ArteraAI Prostate Test in the study.
For more information and to sign up, visit the website or contact direct-ai@artera.ai.
About Artera
Artera is a leading precision medicine company developing AI tests to personalize cancer therapy. Artera offers an AI-enabled test that is the first of its kind to provide both prognostic and predictive results for patients with localized prostate cancer: ArteraAI Prostate Test.
Artera's multimodal artificial intelligence (MMAI) biomarker test leverages a unique algorithm that assesses digital images from a patient's biopsy and their clinical data. The AI combines this information to determine their prognosis and predict whether a patient will benefit from a particular therapy and has been validated using many Phase 3 randomized trials.
Artera's laboratory is CLIA-certified and College of American Pathologists (CAP) accredited. The ArteraAI Prostate Test is clinically available through Artera's laboratory in Jacksonville, Florida, and can be ordered online at Artera.ai.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNET
31 minutes ago
- CNET
More than 40 Percent of Employees Are Using AI at Work
AI is rapidly becoming an integral part of the US workplace. More than 40 percent of US employees are using AI at least a few times a year at work, and that rate is nearly double what it was two years ago, according to a new Gallup poll. The poll asked participants how often they used artificial intelligence in their work role. In 2023, 21 percent of US employees reported using AI at least a few times per year. That number has risen to 40 percent in the latest polling by Gallup. According to the research, use of AI has actually slightly decreased among blue-collar workers over the past two years. Nine percent reported using AI a few times per week or more, down from 10 percent in 2023. That figure is triple for white-collar workers -- 27 percent. Gallup found that the industries with the most frequent AI use are technology (50%), professional services (34%) and finance (32%). AI is increasingly becoming vital to the US workplace, but it remains to be seen how well companies and corporations integrate it into their operations. A report by multinational strategy and management consulting firm McKinsey & Co. said that whereas 92 percent of companies plan to increase their AI investments, a scant 1 percent have deployed AI so that it is "fully integrated into workflows and drives substantial business outcomes." Other notable findings in the Gallup poll include:
CBS News
42 minutes ago
- CBS News
Amazon CEO says AI agents will soon reduce company's corporate workforce
Amazon's CEO envisions an "agentic future" in which AI robots, or agents, replace humans working in the company's offices. In a memo to employees made public by Amazon on Tuesday, CEO Andy Jassy said he expects the company to reduce its corporate workforce as soon as the next few years, as it leans more heavily on Generative AI tools to help fulfill workplace duties. "As we roll out more generative AI and agents, it should change the way our work is done," Jassy stated. "We will need fewer people doing some of the jobs that are being done today, and more people doing other types of jobs." The CEO added that AI will reduce its total corporate workforce as Amazon gets "efficiency gains from using AI extensively across the company." With approximately 1.5 million employees worldwide, the e-commerce giant is the second largest private employer in the United States. Reached for comment, an Amazon spokesperson deferred to the original memo. Amazon shares dipped slightly on Tuesday, down 0.5% as of 2:30 p.m. EST. Amazon investing "quite expansively" in AI Amazon is "investing quite expansively" in generative AI technology, according to Jassy, adding that "the progress we are making is evident." "Many of these agents have yet to be built, but make no mistake, they're coming, and coming fast," the CEO stated in the memo. Amazon ramped up its participation in the generative AI arms race with the release of the Amazon Echo smart speaker in 2014, its first product to include its virtual assistant Alexa. This February, the company announced it was unveiling Alexa+, a new version of the AI-powered voice assistant that's "more conversational, smarter, personalized." AI features have since been incorporated across Amazon's e-commerce websites through tools like "Buy for Me" which allow customers to ask a shopping assistant to buy an item for them and "Recommended Size" which predicts your clothing size based on past purchases. Amazon's AI shopping assistant is currently used by tens of millions of customers, according to Jassy. The company currently has 1,000 Generative AI services and applications in progress or built, he said.
TechCrunch
43 minutes ago
- TechCrunch
Meta is reportedly building AI smart glasses with Prada, too
In Brief Meta is working on a pair of AI smart glasses with the Italian high fashion brand, Prada, according to a report from CNBC on Tuesday. It's unclear at this time when Meta's Prada smart glasses will be publicly announced. The reported Prada collaboration signifies that Meta aims to bring its AI smart glasses technology to more fashion companies outside of its relationship with eyewear giant EssilorLuxottica. Until now, Meta has collaborated closely with EssilorLuxottica and its numerous brands. Prada is not owned by EssilorLuxottica, although the fashion brand has relied on the company to help build its eyewear for decades and the companies just renewed their partnership. Meta has already sold millions of Ray Ban Meta AI smart glasses. Earlier this week, the company teased a collaboration with another EssilorLuxottica brand, Oakley, as Bloomberg previously reported. CNBC reports that those Oakley smart glasses, which could be announced as soon as Friday, may cost around $360.
